Two crystallographers who retracted a Structure paper last year have retracted a study about a similar subject in the Proceedings of the National Academy of Sciences, for similar reasons.
Here’s the notice for the paper, which has been cited 23 times, according to Thomson Scientific’s Web of Knowledge: Continue reading PNAS retraction marks second for crystallography group
When Renewable and Sustainable Energy Reviews accepted a paper last year arguing that nuclear power is Iran’s “assured right,” the editor, Lawrence Kazmirski, thought the article would be at least somewhat controversial. He was right — but for the wrong reason.
Shortly after publication, Kazmirski, director of the National Center for Photovoltaics at the National Renewable Energy Laboratory, in Golden, Colo., received an email from one of the listed co-authors of the article complaining that he and another co-author had not consented to submit the work. Kazmirski contacted the lead author, Afshin Mazandarani, who agreed to withdraw the paper.
The result was the following notice, which appeared in October (we only recently saw it): Continue reading Should Iran have nuclear power? Paper addressing question retracted for authorship issues
Following an investigation by the State University of New York (SUNY) Upstate into the work of one of its neuroscientists, the Journal of Neurochemistry has retracted a 2007 paper.
The retraction notice is quite clear about why the paper is being withdrawn: Continue reading Journal of Neurochemistry retracts paper after SUNY Upstate medical school finds evidence of fraud
The authors of a paper in the Journal of Biological Chemistry (JBC) have retracted it, but don’t ask us why.
This being the JBC, the retraction notice for “Human T-cell Leukemia Virus Type I Tax Down-regulates the Expression of Phosphatidylinositol 3,4,5-Trisphosphate Inositol Phosphatases via the NF-κB Pathway” is the very definition of opaque: Continue reading Mysterious retraction in the Journal of Biological Chemistry for Takashi Tsuji’s group
Today, without us having planned it, has become the day of retracted papers that found a new home.
This morning, we posted an item about a chimp “culture” paper that was retracted from Biology Letters after its authors found some errors, and then published, with corrections, in the Journal of Human Evolution. This afternoon, we bring you the news of a PLoS ONE paper on longevity genes that is the corrected version of a Science paper retracted last year: Continue reading Sebastiani and Perls longevity genes work finds a new home in PLoS ONE following Science retraction
Last week, we brought you the tale of a paper about camels that was rejected on submission, but published accidentally, and then retracted. It turns out this was not a unique occurrence.
An eagle-eyed Retraction Watch reader emailed us about another such paper, this one in the Journal of Nanoparticle Research. The study, “Growth of gold flowers on polyacrylonitrile fibers,” appears to have been published online on December 3, 2008. It now sports this retraction notice: Continue reading Another paper rejected, mistakenly published, then retracted, this one in nanotechnology journal
In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.”
Harvard’s David Sinclair went further, telling The New York Times that he didn’t know who Das was: Continue reading So how peripheral was Dipak Das’ resveratrol work, really?
Many Retraction Watch readers will now be familiar with the case of Dipak Das, the resveratrol researcher about whom the University of Connecticut issued a voluminous report yesterday — summary here — detailing 145 counts of data fabrication and falsification. This has been a fast-moving story, so we wanted to highlight a number of updates to our original post, and offer a few more.
First, we have confirmed with publisher Mary Ann Liebert this morning that Das has been relieved of his duties as co-editor in chief of Antioxidants & Redox Signaling. He had shared that post with Chandan Sen, and his name as been removed from the masthead of that journal. Here’s a statement from the publisher: Continue reading Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges
In our 2011 year-end post, we promised to keep
…an eye on what may be an emerging trend: The mega-correction. We’ve seen errata notices that correct so many different errors, it’s hard to believe the paper shouldn’t have been retracted. It’s unclear what this means yet, but watch this space for coverage of more examples.
We’ve found another example in the Journal of Cell Science, “Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells,” originally published in September 2011. The correction begins with what turns out to be a bit of an understatement: Continue reading A mega-correction, but no retraction, in the Journal of Cell Science
The University of Connecticut, in what clearly seems like an attempt to get ahead of damaging news, has announced an “extensive” investigation into research misconduct involving one of its scientists, Dipak K. Das.
According to a press release, the university has notified 11 journals that published Das’ work about the alleged fraud. One area of interest for Das, a government-funded professor of surgery and director of the Cardiovascular Research Center, has been resveratrol, a substance in red wine that has allegedly been linked to improved cardiac health.
The university touted some of his early efforts in this field.
[Please also see our update posted Thursday.]
Here’s what the release has to say: Continue reading UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case
